Shots:
Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues
In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved
For a…
Shots:
Transforming care with advanced mechanisms of action, monoclonal antibody therapies hold a strong foothold in the healthcare market
In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Keytruda with $25.01B revenue ranks first in our list followed by…
Previously in PharmaShots Magazine, we explored Companion Animals as a theme. For the September Edition, our theme is centered on livestock animals. Livestock farming remains one of the key sectors in agrarian economies like India, China, and Latin American countries. Livestock farming provides us with milk and meat enriched with essential nutritional compounds like protein. …
Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies.
By leveraging Sapient's real-world data asset, the…
Shots:
An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies
In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com
Established in 1993 in San Francisco, California,…
Shots:
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients
The major highlights were the US FDA’s approval of Sandoz’s Enzeevu for Treating Neovascular Age-Related…
Shots:
With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare
In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 16 small molecules, 5 biologics, 11 cell & gene therapies, 1 recombinant protein, 1 vaccine, 1 immunotherapy, 1 radiopharmaceutical, 1 antisense oligonucleotide, 3 RNA therapies 1 herbal medicine…
Shots:
In the August Edition of the Know Your Investor series, we bring a condensed yet illuminating report on Arch Venture Partners
In 2023, Arch Ventures Partners participated in 6 investment rounds and added 27 companies focusing on biopharma and manufacturing & services to its portfolio
For a detailed report on all the investments, reach…
Shots:
Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers
Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma
The study reveals that four out of the ten patients received only…

